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Authors’ responseMedullary thyroid cancer (MTC) can be hereditary or
sporadic. The latter means that the patient only has MTC
with no other endocrinopathies, e.g., pheochromocytoma
or hyperparathyroidism, and no other family member has
MTC. However, apparently sporadic MTC can be hereditary,
after a germline study of RET mutations and some typical
changes of codon were found. We have published a study1
and examined RET mutations in sporadic MTC patients,
using polymerase chain reaction (PCR)-based sequencing.
DNA was extracted from tumor tissue and peripheral blood
leukocytes of seven unrelated individuals with apparently
sporadic MTC. Oligonucleotide primers were selected to
amplify exons 10, 11, 13, 15, and 16 of the RET proto-
oncogene, to examine the sequences of codons 609, 611,
618, and 620 of exon 10, codon 634 of exon 11, codon 768 of
exon 13, codon 883 of exon 15, and codon 918 of exon 16.
Direct DNA sequencing from PCR products was then per-
formed. The results showed that one patient had a somatic
mutation at codon 918, one patient had a de novo germline
mutation at codon 634 (TGC–>CGC). Another patient had
a germline mutation at codon 634 (TGC–>TTC). In the
remaining four cases, no RET mutations were found. Our
findings suggest that all patients with apparently sporadic
MTC should be screened for the RET protooncogene, by
molecular analysis.
Although RET genetic screening of sporadic MTC allows
the preclinical diagnosis of unsuspected gene carriers and
the identification of a relevant percentage of hidden
familial MTC, Romei et al. only discovered an unsuspected
germline RET mutation in 47 of 729 (6.5%) of apparently
sporadic MTC patients who were re-classified as having
hereditary MTC.2 It is not cost-effective, especially when
there is no health reimbursement for the screening, such as
in Taiwan.0929-6646/$ - see front matter Copyright ª 2011, Elsevier Taiwan LLC
doi:10.1016/j.jfma.2011.09.018In our recently published study,3 although somatic RET
mutation was not performed in these seven sporadic MTC
patients, all possible mutation points were thoroughly
checked. Any gene carriers should have been found. On the
other hand, RET mutations, although prevalent in MTC
subjects, have not yet been proven to predict whether
patients will respond to multikinase inhibitors,4 even if
somatic mutation of the tumor is known.
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